If you are one of the investors interested in Editas Medicine stock, in the field of biotechnologies, we offer you our help in the analysis of this value. In this article, we will explain how to set up these analyses thanks to detailed information concerning this company, its activities and sources of profit, its main opponents on the market or its recent partnerships. We will also explain what data to use to perform a fundamental analysis of this stock.
With regard to the sector of activity in which this company is active, you will of course have to be interested in the research currently carried out by this one with the various phases of tests and clinical trials until the marketing authorizations are obtained.
It will also be necessary to keep an eye on the group's strategic partnerships with pharmaceutical companies with a view to financing new projects as well as on the marketing of licenses that will be profitable for it.
The competition in this sector of activity must also be studied closely with the research of other companies working in the same therapeutic areas and market events.
Finally, it will of course be necessary to keep an eye on the group's financial results and to compare them, from one year to the next, with analysts' forecasts in order to assess growth.
We now propose you to learn a little more about the company Editas Medicine and its sector of activity. Indeed, through this presentation of the group, we will explain to you the areas in which it operates and what its economic model is.
Editas Medicine Inc. is an American biotechnology company. More specifically, the company specializes in clinical-stage gene editing. The company focuses its activities on the development of transformative gene-editing drugs for a range of serious diseases.
The company is active in the development and commercialization of genome technology and is developing a genome editing platform based on CRISPR technology that uses a protein-ribonucleic acid or RNA complex composed of a CRISPR-associated enzyme linked to a guide RNA molecule designed to recognize a specific deoxyribonucleic acid or DNA sequence.
The company focuses on in vivo gene editing drugs where the drug is injected or infused into the patient with the goal of modifying the cells inside the body and ex vivo gene editing cell drugs where the cells are modified with its technology.
Currently, the American group employs 235 people.
Now that you are familiar with the company Editas Medicine and its activities, we propose to introduce you to the different competitors in its sector of activity and some information about them:
This Swiss-American company is a biotechnology company based in Zug, Switzerland, and currently employs approximately 304 people. With a market capitalization of more than $13 billion, the group has research and development activities in Massachusetts.
This company specializes in the development of diagnostic tests for genetic diseases and genomic analysis of cancers. The company uses molecular combing technology that allows direct visualization of individual DNA molecules to detect quantitative and qualitative variations in the genome in order to establish their role in a targeted pathology.
This company is a preclinical stage biotechnology company that offers a unique solution for antibody discovery from target to IND application. The group thus offers therapeutic antibody activities, in vivo and ex vivo with preclinical studies, CMC/CDMO among others.
This company is a French biotechnology company specialized in antibody engineering that was founded in 1995. It is specialized in the research of high quality antibodies and powerful tools in order to accelerate its research. It is one of the leaders in biotechnology in France but also in the world.
After having learned about the activities of the Editas Medicine group and its direct competitors, we propose to discover who its partners and strategic allies are. Indeed, Editas Medicine regularly forms alliances with other companies as in these two examples:
In 2021, the group signed a research and development partnership with Allergan, with the latter to gain exclusive access and the ability to license up to 5 Editas genome editing eye programs. Allergan will pay Editas Medicine $90 million for the development of five treatment candidates and associated programs. The agreement includes Editas' lead drug program called LCA10, which is in preclinical development for the treatment of a rare inherited eye disorder called Leber's congenital amberosis. The agreement also provides for additional payments to Editas for the achievement of milestones related to LCA10.
In the same year, the group partnered with Genomic Vision to accelerate the development of the use of CRISPR-Cas 9 molecular scissors for at least one year. Editas is using CRISPR-Cas 9 to cut out defective genes and replace them with other genes to treat rare eye diseases, cancers and genetic diseases that affect the lung and muscles. According to specialists in this field, these would be one of the major innovations of our century in the field of neuroscience in particular.
A part of the capital of Editas Medicine is owned by large private or institutional investors, including ARK Investment Management with 9.23% of the shares, the Vanguard Group with 9.15%, Nikko Asset Management Americas with 6.24%, SSgA Funds Management with 3.71%, Polaris Growth Management with 2.63%, Flagship Pioneering with 2.45%, BlackRock Fund Advisors with 2.43%, Nikko Asset Management Co. with 2.22%, CaaS Capital Management with 2.05% and Capital Research Management with 1.90%.
When performing technical analysis on Editas Medicine stock, you will need to use several major trend and volatility indicators. These include moving averages, MACD, stochastic indicators, RSI, support and resistance levels, Bollinger bands and other such indicators. The more indicators you use, the better the signals will be.
To invest in the Editas Medicine share price, you have several options. The first is to buy this share with a classic stock market investment product such as a securities account. But you can also speculate directly on the price of this stock by using derivatives such as CFDs or contracts for difference, which allow you to invest without owning this stock.
eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.
Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.
Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.
Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.
Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.
